

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Vancomycin Strides (Vancomycin):

This is a summary of the risk management plan (RMP) for Vancomycin Strides. The RMP details important risks of Vancomycin Strides, how these risks can be minimized and how more information will be obtained about Vancomycin Strides's risks and uncertainties (missing information).

Vancomycin Strides's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Vancomycin Strides should be used.

Important new concerns or changes to the current ones will be included in updates of Vancomycin Strides's RMP.

I. The medicine and what it is used for:

Vancomycin Strides is authorized in patients 12 years and older for the treatment of Clostridium difficile infection (CDI).

It contains Vancomycin as the active substance, and it is given by the oral route.

II. Risks associated with the medicine and activities to minimize or further characterize the risks:

Important risks of Vancomycin Strides, together with measures to minimize such risks and the proposed studies for learning more about Vancomycin Strides's risks, are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals.
- Important advice on the medicine's packaging.
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without Prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A. List of important risks and missing information

Important risks of Vancomycin Strides are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely administered.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Vancomycin Strides. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B. Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C. Post Authorisation Development Plan

II.C.1 Studies Which Are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Vancomycin Strides.

II.C.2 Other Studies in Post Authorisation Development Plan

There are no studies required for Vancomycin Strides.